The coagulation system as a target for experimental therapy of human gliomas.
The purpose of this paper is to review the rationale for the development of coagulation-reactive drugs for the experimental therapy of gliomas. Numerous reactants familiar to students of blood coagulation have been shown to contribute to neoplastic proliferation, invasion and metastasis. Recently, considerable progress has been made in demonstrating the ability of drugs capable of inhibiting these reactants to alter cancer progression. Biological features of gliomas within the realm of blood coagulation suggest that clinical trials of such drugs warrant consideration. This approach offers the prospect of a novel treatment for this devastating tumour type that does not share the toxicities of conventional cancer therapies.
Loynes
J T
JT
Section of Hematology/Oncology, DartmouthHitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03257, USA. James.T.Loynes@Hitchcock.org
Zacharski
L R
LR
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D007611:Aprotinin / Q000494:pharmacology / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001932:Brain Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015951:Factor Xa / Q000502:physiology; D005910:Glioma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D008074:Lipoproteins / Q000502:physiology; D013917:Thrombin / Q000502:physiology; D018180:Thrombomodulin / Q000502:physiology; D019851:Thrombophilia / Q000097:blood / Q000188:drug therapy*; D013925:Thromboplastin / Q000502:physiology; D014568:Urokinase-Type Plasminogen Activator / Q000502:physiology
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D018180:Thrombomodulin; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin; D013925:Thromboplastin; D007611:Aprotinin; D013917:Thrombin; D015951:Factor Xa; D014568:Urokinase-Type Plasminogen Activator